Neurocrine biosciences presents patient-reported outcomes from kinect-pro™ study demonstrating ingrezza® (valbenazine) capsules improved functionality and quality of life in patients with tardive dyskinesia

Kinect-pro is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales patients taking ingrezza reported robust and clinically meaningful improvements in physical, social and emotional functioning improvements were seen as early as week 4 after initial treatment with the lowest ingrezza dose and sustained through week 24 even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with ingrezza treatment san diego , june 2, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced new data from the phase 4 kinect-protm open-label study demonstrating robust and sustained improvements in physical, social and emotional functioning in patients with tardive dyskinesia taking once-daily ingrezza® (valbenazine) capsules. kinect-pro is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment, specifically ingrezza, on tardive dyskinesia using multiple clinically validated scales, including the tardive dyskinesia impact scale.
NBIX Ratings Summary
NBIX Quant Ranking